136 related articles for article (PubMed ID: 33876576)
1. Human Mass Balance and Metabolite Profiling of [
Mu S; Palmer D; Fitzgerald R; Andreu-Vieyra C; Zhang H; Tang Z; Su D; Sahasranaman S
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1108-1120. PubMed ID: 33876576
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
3. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
4. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
Xu B; Yin Y; Dong M; Song Y; Li W; Huang X; Wang T; He J; Mu X; Li L; Mu S; Zhang W; Li M
Cancer Med; 2021 Jan; 10(1):109-118. PubMed ID: 33128299
[TBL] [Abstract][Full Text] [Related]
5. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Lickliter JD; Voskoboynik M; Mileshkin L; Gan HK; Kichenadasse G; Zhang K; Zhang M; Tang Z; Millward M
Br J Cancer; 2022 Mar; 126(4):576-585. PubMed ID: 34795408
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
7. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
[TBL] [Abstract][Full Text] [Related]
9. Pamiparib: First Approval.
Markham A
Drugs; 2021 Jul; 81(11):1343-1348. PubMed ID: 34287805
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and Disposition of Siponimod, a Novel Selective S1P
Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
[TBL] [Abstract][Full Text] [Related]
11. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.
Bian Y; Meng J; Ma S; Li G; Wang Y; Li S; Liu L; Huang C; Zhang H; Zhong D; Miao L
Br J Clin Pharmacol; 2022 Jul; 88(7):3307-3320. PubMed ID: 35112382
[TBL] [Abstract][Full Text] [Related]
12. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.
Ciardiello F; Bang YJ; Cervantes A; Dvorkin M; Lopez CD; Metges JP; Sánchez Ruiz A; Calvo M; Strickland AH; Kannourakis G; Muro K; Kawakami H; Wei J; Borg C; Zhu Z; Gupta N; Pelham RJ; Shen L
Cancer Med; 2023 Jun; 12(12):13145-13154. PubMed ID: 37260158
[TBL] [Abstract][Full Text] [Related]
14. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Xiong Y; Guo Y; Liu Y; Wang H; Gong W; Liu Y; Wang X; Gao Y; Yu F; Su D; Wang F; Zhu Y; Zhao Y; Wu Y; Qin Z; Sun X; Ren B; Jiang B; Jin W; Shen Z; Tang Z; Song X; Wang L; Liu X; Zhou C; Jiang B
Neoplasia; 2020 Sep; 22(9):431-440. PubMed ID: 32652442
[TBL] [Abstract][Full Text] [Related]
15. Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes.
de Vries R; Jacobs F; Mannens G; Snoeys J; Cuyckens F; Chien C; Ward P
Drug Metab Dispos; 2019 May; 47(5):453-464. PubMed ID: 30787101
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans.
Lee CA; Yang C; Shah V; Shen Z; Wilson DM; Ostertag TM; Girardet JL; Hall J; Gillen M
Drug Metab Dispos; 2018 May; 46(5):532-541. PubMed ID: 29490903
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.
Jiang J; Bao X; Yue Y; Schiff D; Bindra R; Li J
Biomed Chromatogr; 2022 Dec; 36(12):e5478. PubMed ID: 35938683
[TBL] [Abstract][Full Text] [Related]
20. Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
Wu X; Zhu J; Wang J; Lin Z; Yin R; Sun W; Zhou Q; Zhang S; Wang D; Shi H; Gao Y; Huang Y; Li G; Wang X; Cheng Y; Lou G; Gao Q; Wang L; Du X; Pan M; Mu X; Li L; Li M; Mu S; Kong B
Clin Cancer Res; 2022 Feb; 28(4):653-661. PubMed ID: 34844979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
